Background: High factor-VII activity has recently been recognized as an independent risk factor for coronary artery disease. The aim of the present study was to determine whether high levels of factor-VII activity in elderly patients are caused by endothelial cell injury and are related to vascular disease through activation of the coagulation system.
Methods: We studied 27 asymptomatic healthy elderly men with high factor-VII activity (155–206%) and 22 healthy elderly men with low factor-VII activity (96–122%) selected from 246 men over 60 years of age attending annual health examinations. We also studied 36 patients with vascular disease (22 with coronary artery disease and 14 with chronic cerebral infarction).
Results: The levels of endothelium-derived markers (thrombomodulin, tissue plasminogen activator-plasminogen activator inhibitor-1 complex, active plasminogen activator inhibitor 1 and tissue factor pathway inhibitor) did not differ between the subjects with high and those with low factor-VII activity. We therefore conclude that high factor-VII activity is not primarily caused by endothelial cell injury. The high-factor-VII group had higher levels of coagulation inhibitors (protein C, antithrombin III and heparin cofactor II), coagulation activation markers (prothrombin fragment 1+2, D-dimer and plasmin-α2-plasmin-inhibitor complex), lipoprotein (a) and total cholesterol than the low-factor-VII group. The coagulation and lipid profiles of the group with vascular disease were closer to those of the high-factor-VII group than to those of the low-factor-VII group; the same was true of elevated active plasminogen activator inhibitor-1 levels.
Conclusion: High factor-VII activity in the elderly is accompanied by hyperlipidaemia, including increased levels of lipoprotein (a), and leads to coagulation activation in vivo. Thus, elderly people with high factor-VII activity are predisposed to vascular disease.
MeadeTWMellowSBrozovicMMillerGJChakrabartiRRNorthWRS: Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet1986, ii:533–537.
2.
MeadeTWRuddockVStirlingYChakrabartiRMillerGJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet1993, 342:1076–1079.
3.
KarioKMatsuoT: Coronary artery disease and factor VII hyperactivity in the elderly Japanese. Am J Cardiol1992, 69:807–809.
4.
KarioKMatsuoTNakaoK: Factor VII hyperactivity in the elderly. Thromb Haemost1991, 65:25–27.
5.
MeadeTWCooperJMillerGJHowarthDJStirlingY: Antithrombin III and arterial disease. Lancet1991, 337:850–851.
6.
KarioKMatsuoTKobayashiH: Heparin cofactor II deficiency in the elderly: Comparison with antithrombin III. Thromb Res1992, 66:489–498.
7.
KarioKMatsuoTKarioTKobayashiH: Sex-related differences in the relationship between plasma factor VII levels and serum lipids, lipoproteins, and apolipoproteins. Thromb Res1991, 64:769–773.
8.
HoffmanCJMillerRHHultinMB: Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb1992, 12:267–370.
9.
Hijikata-OkunomiyaAFunaharaYOpartkiattikulN: An evaluation of prothrombin assay method using MD805 by means of warfarin-treated plasma. Thromb Res1991, 64:559–569.
10.
VinazzerHStockerK: Heparin cofactor II: Experimental approach to a new assay and clinical results. Thromb Res1991, 61:235–241.
11.
MartinoliJLStockerK: Fast functional protein C using protac, a novel protein C activator. Thromb Res1986, 43:253–264.
12.
PelzerHSchwarzAStuberW: Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost1991, 65:153–159.
13.
PelzerHSchwarzAHeinburgerN: Determination of human thrombin-antithrombin III complex on plasma with an enzyme-linked immunosorbent assay. Thromb Haemost1988, 59:101–106.
14.
MimuroJKoikeYSumiYAokiN: Monoclonal antibody to discrete regions in α2-plasmin inhibitor. Blood1987, 69:446–453.
15.
SakataYMurakamiTNoroAMoriKMatsudaM: The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood1991, 77:1949–1957.
16.
TakanoSKimuraSOhdamaSAokiN: Plasma thrombomodulin in health and diseases. Blood1990, 76:2024–2029.
17.
MimuroJSakataYWakabayashiKMatsudaM: Level of protein C determined by combined assays during disseminated intravascular coagulation and oral anticoagulation. Blood1987, 69:1704–1711.
18.
SoriaCSoriaJMirshahiMcMirshahiMDunnicaSBoucheixC: Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination. Thrornb Res1987, 45:383–392.
19.
SandsetPMLarsenMLAbildgaardULindahlAKOdegaardOR: Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis1991, 2:425–433.
20.
RhoadsGGDahlenGBergKMortonNEDannenbergAL: Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA1986, 256:2540–2544.
21.
MeadeTWDyerSHowarthDJImesonJDStirlingY: Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol1990, 74:77–61.
22.
HoffmanCShahASodumsMHultinMB: Factor VII activity state in coronary artery disease. J Lab Clin Med1988, 111:475–481.
23.
HoffmanCMillerRHLawsonWEHultinMB: Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol1989, 14:941–946.
24.
SuzukiTYamuchiKMatsushitaTFurumichiTFuruiHTsuzukiJ: Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol1991, 14:731–736.
25.
KitchenSMaliaRGPrestonFE: A comparison of methods for the measurement of activated factor VII. Thromb Haemost1992, 68:301–305.
26.
BalleisenLAssmannGBaileyJEppingP-HSchulteHvan de LooJ: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost1985, 54:721–723.
27.
PhillipsGBJingT-YResnickLMBarbaglloMLaraghJHSealeyJE: Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens1993, 11:699–702.
28.
JonesDWMackieIJWinterMGallimoreMMachinSJ: Detection of protein C deficiency during oral anticoagulant therapy: Use of the protein C: Factor VII ratio. Blood Coagul Fibrinolysis1991, 2:407–411.
29.
SchernthanerGVokuvichTKnoblPHayUMullerMM: The effect of near-normoglycaemic control on plasma levels of coagulation factor VII and anticoagulant proteins C and S in insulin-dependent diabetic patients. Br J Haematol1989, 73:356–359.
30.
KarioKMatsuoTTaiSSakamotoSYamadaTMikiT: Congenital protein C deficiency and myocardial infarction: Concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis. Thromb Res1992, 67:95–103.
31.
IshiiHNakanoMTsubouchiJIshikawaTUchiyamaHHiraishiS: Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost1990, 63:157–162.
32.
MitropoulosKAEsnoufMP: The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. Thromb Res1990, 57:541–549.
